MetLife Investment Management’s ACELYRIN SLRN Stock Holding History

MetLife Investment Management’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,493	Closed	-$45.7K	–	2916
2025 Q1	$45.7K	Sell	18,493 -24,359	-57%	-$57.9K	﹤0.01%	2698
2024 Q4	$135K	Hold	42,852	–	–	﹤0.01%	2491
2024 Q3	$211K	Hold	42,852	–	–	﹤0.01%	2260
2024 Q2	$189K	Buy	42,852 +4,651	+12%	+$21.8K	﹤0.01%	2279
2024 Q1	$258K	Buy	38,201 +20,042	+110%	+$152K	﹤0.01%	2054
2023 Q4	$135K	Hold	18,159	–	–	﹤0.01%	2453
2023 Q3	$185K	Buy	+18,159	New	+$386K	﹤0.01%	2264

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MetLife Investment Management's SLRN Position: Q2 2025 in Review

MetLife Investment Management sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 18,493 shares — an estimated $45.7K sold.

MetLife Investment Management first reported a position in SLRN in Q3 2023 and held it in 7 quarters. The position peaked at $258K in Q1 2024. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

MetLife Investment Management reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
MetLife Investment Management sold 18,493 ACELYRIN shares in Q2 2025, an estimated $45.7K.
MetLife Investment Management first reported a position in ACELYRIN in Q3 2023 and held it in 7 quarters.
MetLife Investment Management's ACELYRIN position peaked at $258K in Q1 2024.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.